苦参桂花汤联合介入化疗治疗晚期结肠癌及其对CCSA2和survivin表达的影响

doi:10.3969/j.issn.2095-9400.2019.11.009

摘要
图/表
参考文献
相关文章 (8)

全文: PDF (1305 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨苦参桂花汤联合介入化疗治疗晚期结肠癌的临床效果及其对肿瘤标志物结肠癌特异性抗原2（CCSA2）和生存素（survivin）表达的影响。方法：选取2015年3月至2017年3月诸暨市人民医院就诊的62例晚期结肠癌患者，随机分为观察组（n=31）与对照组（n=31），2组均采用介入化疗方案，观察组在此基础上再给予苦参桂花汤辨证加减，连续观察8周。评价2组患者中医症候的改善情况，以及生活质量评分变化，记录患者的不良反应与生存率，同时检测2组患者肠镜活检肿瘤标志物CCSA2和survivin的表达。结果：经治疗后观察组的中医症候改善情况、总有效率与生活质量评分均优于对照组（P＜0.05），观察组的不良反应发生频次更少，生存率更高（P＜0.05），且经治疗后实验组CCSA2及survivin表达水平均显著降低。结论：苦参桂花汤联合介入化疗治疗晚期结肠癌能够有效改善患者的中医症状，提高患者的生活质量与生存率，显著降低不良反应的发生率，同时抑制肿瘤标志物CCSA2及survivin的表达。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蒋莹华

关键词 ：苦参桂花汤, 介入化疗, 结肠肿瘤, 结肠癌特异性抗原2, 生存素

Abstract：Objective: To investigate the clinical effect of KushenGuihua Decoction combined with interventional chemotherapy in the treatment of advanced colon cancer and its effect on the expression of colon cancer specific antigen 2 (CCSA2) and survivin as tumor markers. Methods: Sixty-two patients with colon cancer in our hospital were randomly divided as experimental group (n=31) and control group (n=31). Based on the treatment with interventional chemotherapy in both groups, the experimental group was given KushenOsmanthus Decoction for 8 weeks. The improvement in traditional Chinese medicine symptoms and changes of life quality scores were evaluated in two groups. Adverse reactions and survival rate of the patients were recorded. Meanwhile, the expression of CCSA2 and survivin in both groups was detected. Results: After treatment, the traditional Chinese medicine symptoms improved; the total effective rate and the life quality score in the experimental group were better than the control group (P<0.05). Moreover, the frequency of adverse reactions in the experimental group was lower than that in the control group (P<0.05) while the survival rate was much higher (P<0.05). The expression levels of CCSA2 and survivin in the experimental group were significantly decreased after treatment. Conclusion: KushenGuihua Decoction combined with interventional chemotherapy can effectively improve the symptoms of patients with advanced colon cancer and the life quality as well. Meanwhile, it can increase the survival rate but reduce the incidence of adverse reactions in patients and inhibit the expression of CCSA2 and survivin as tumor markers.

Key words： KushenGuihua Decoction interventional chemotherapy colonic neoplasms colon cancer specific antigen 2 survivin

收稿日期: 2019-04-02

基金资助:绍兴市医药卫生科技计划项目（2018C30145）。

作者简介: 蒋莹华（1983-），女，浙江诸暨人，主治中医师。

链接本文:

https://xb.wmu.edu.cn/CN/10.3969/j.issn.2095-9400.2019.11.009 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I11/832

[1] 刘希双, 刘思良, 王光兰, 等. 结肠良恶性肿瘤的关系及其发病规律[J]. 世界华人消化杂志, 2005, 13(10): 1235-1238.
[2] 殷淑媛, 王瑞平, 邹玺, 等. 常春藤皂苷元与5-氟尿嘧啶或奥沙利铂联用对人结肠癌HT-29细胞增殖的影响[J]. 中医杂志, 2015, 56(7): 602-606.
[3] 周懿明, 徐婧, 宋怡琳. 中西医结合治疗大肠癌的研究进展[J]. 中西医结合心血管病电子杂志, 2017, 5(29): 175-176.
[4] 商斌. 介入化疗联合口服替吉奥胶囊治疗进展期胃癌的疗效和安全性分析[J]. 中国现代医生, 2014, 52(3): 146-147, 151.
[5] AKIYAMA Y, KIMURA Y, ENATSU R, et al. Advantages and disadvantages of combined chemotherapy with carmustine wafer and bevacizumab in patients with newly diagnosed glioblastoma: a single-institutional experience[J]. World Neurosurg, 2018, 113: 508-508, 514.
[6] 刘声, 王笑民, 杨国旺, 等. 扶正防癌方联合化疗对晚期结肠癌患者生活质量及免疫功能的影响[J]. 世界中医药, 2015, 10(2): 209-211, 215.
[7] 靖大道, 萧树东. 结肠癌病因学研究现状[J]. 胃肠病学, 2001, 6(4): 228-230.
[8] LEWIS C, XUN P, HE K. Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up [J]. Support Care Cancer, 2016, 24(10): 4081-4082.
[9] DOUILLARD J Y, ZEMELKA T, FOUNTZILAS G, et al. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study[J]. Clin Colorectal Cancer, 2014, 13(1): 14-26.
[10] 陈占涛. 补中益气汤联合化疗治疗结肠癌手术后的远期效果分析[J]. 中西医结合心血管病电子杂志, 2016, 4(14): 130-131.
[11] 赵晓宁, 薛文翰. 健脾化瘀方联合化疗治疗晚期胃癌疗效及对生活质量的影响[J]. 中医药学报, 2016, 44(3): 105-108.
[12] 王强. 扶正消积汤联合吉西他滨及顺铂治疗非小细胞肺癌临床研究[J]. 光明中医, 2017, 32(22): 3306-3307, 3326.
[13] 赵福军, 刘松江. 刘松江教授治疗大肠癌四法浅谈[J]. 中国医疗前沿, 2010, 5(20): 51-52.
[14] AMBROSINI G, ADIDA C, ALTIERI D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997, 3(8): 917-921.
[15] 金晓昇, 安慧敏, 黄智铭. 生存素和PTEN在良恶性胃溃疡中的表达[J]. 温州医科大学学报, 2017, 47(6): 456-458.
[16] WANG T, LIU Z, ZHANG Z, et al. Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo[J]. Oncol Lett, 2017, 14(2): 2001-2008.
[17] LI S, YANG Y, DING Y, et al. Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer[J]. Oncol Lett, 2017, 14(3): 3774-3779.
[18] IKEGUCHI M, KAIBARA N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma[J]. Br J Cancer, 2002, 87(8): 883-887.
[19] 谷化平, 尚培中, 冯骥良. 原发性胆囊癌中survivin和nm23H1表达及其临床病理的相关性研究[J]. 临床肝胆病杂志, 2006, 22(4): 252-253.
[20] SHARIAT S F, LOTAN Y, SABOORIAN H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma[J]. Cancer, 2004, 100(4): 751-757.
[21] 李志, 刘卫红, 王青, 等. 抗肿瘤相关抗原Imp1、p62、Koc、
p53、c-myc的抗体联合检测对结肠癌诊断的价值[J]. 中国卫生检验杂志, 2012, 22(7): 1484-1486.